FDA approves Novo Nordisk's semaglutide as obesity treatment
The US FDA has given the thumbs-up to Novo Nordisk's semaglutide as an injection-based treatment for obesity. This paves the way for massive sales for the Danish pharmaceutical company.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
There is an air of celebration at Novo Nordisk's headquarters, as the US Food and Drug Administration (FDA) has just approved the pharmaceutical company’s application for the use of semaglutide as a treatment for obesity marketed as Wegovy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
